TEGISON
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGISON is an oral small-molecule capsule approved in 1986 by Roche. The mechanism of action and specific indications are not publicly detailed in available data. Patient population and therapeutic use remain undisclosed.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting shrinking team and transition focus toward generic transition or portfolio reallocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring; roles are primarily mature commercial maintenance positions. Career development on TEGISON is limited given the LOE-approaching lifecycle and shrinking product focus.
Brand ManagerField Sales
Worked on TEGISON at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.